Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FNTA | P49354 | 12/20 | 0.49 |
| ▸ | FNTB | P49356 | 12/20 | 0.49 |
| ▸ | PGGT1B | P53609 | 7/20 | 0.49 |
| ▸ | CYP11B1 | P15538 | 2/20 | 0.46 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.46 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6756369 | 0.92 | FNTA (0.49) | FNTAFNTBPGGT1BKCNH2 | |
| SCHEMBL6758386 | 0.87 | CYP11B1 (0.46) | FNTAFNTBPGGT1BCYP11B1CYP11B2 | |
| SCHEMBL6758390 | 0.86 | CYP11B1 (0.45) | FNTAFNTBPGGT1BCYP11B1CYP11B2 | |
| SCHEMBL6755054 | 0.84 | FNTA (0.46) | FNTAFNTBPGGT1BCYP11B1CYP11B2 | |
| SCHEMBL6757421 | 0.83 | FNTA (0.57) | FNTAFNTBPGGT1BCYP11B1CYP11B2 | |
| SCHEMBL6756352 | 0.83 | FNTA (0.52) | FNTAFNTBPGGT1BCYP11B1CYP11B2 | |
| SCHEMBL6758407 | 0.82 | FNTA (0.53) | FNTAFNTBPGGT1BCYP11B1CYP11B2 | |
| SCHEMBL6759301 | 0.81 | FNTA (0.54) | FNTAFNTBPGGT1BCYP11B1CYP11B2 | |
| SCHEMBL6758383 | 0.81 | FNTA (0.43) | FNTAFNTBCYP11B1CYP11B2KCNH2 | |
| SCHEMBL6865126 | 0.80 | FNTA (0.45) | FNTAFNTBKCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040204417-A1 | Novel benzothienyl or indole derivatives, preparation and use thereof as inhibitors of prenyl transferase proteins | PIERRE FABRE MEDICAMENT (FR) | 2004-10-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040204417-A1 | Novel benzothienyl or indole derivatives, preparation and use thereof as inhibitors of prenyl transferase proteins | CBR1, CBR3, HCCS | FNTA 338/4885FNTB 215/4885PGGT1B 905/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.